|
|
|
| Effect of Somatostatin, Ulinastatin Combined with Oxymatrine on Intestinal Mucosal Barrier Damage in Severe Pancreatitis and HMGB1 Level |
| Ma Deyuan, et al |
| Xining First People's Hospital,Qinghai Xining 810000,China |
|
|
|
|
Abstract Objective: To investigate the effect of oxymatrine on intestinal mucosal barrier damage and HMGB1 level in patients with severe pancreatitis.Method: A total of 120 patients with severe pancreatitis were selected as the research object,and were randomly vided into observation group and control group.The control group was given basic treatment,while the observation group was treated with Oxymatrine on the basis of the control group.The white blood cell recovery time,inflammatory factor level and intestinal mucosal barrier damage index level were observed.Results: The total effective rate of observation group was 93.33%,which was significantly higher than that of control group,P＜0.05;The abdominal pain relief time (3.58±1.02) d,first defecation time (3.09±0.68) d,blood amylase recovery time (4.58±1.45) d and white blood cell recovery time (5.05±1.33) d in the observation group were significantly lower,P＜0.05;After treatment,the levels of TNF-α(887.65±133.24)ng/L,IL-6(64.75±22.31)ng/L,IL-1(388.65±83.06)ng/L and HMGB1(32.43±23.67)μg/mL in the observation group were significantly lower,P＜0.05;After treatment,the levels of serum DAO (8.16±2.04) U/L,serum D-lactic acid (6.51±0.53) mg/L and botulinum toxin (16.42±6.87) EU/L in the observation group were significantly lower,P＜0.05.Conclusion: Oxymatrine combined with basic treatment for severe pancreatitis has significant clinical effect,can significantly reduce the level of inflammatory factors,improve the intestinal mucosal barrier function of patients,and is worthy of clinical application.
|
|
|
|
|
|
[1] 王刚,韩俊岭,王放,等.胃肠道动力障碍的相关因子在家兔重症急性胰腺炎模型的变化[J].河北医学,2019,25(2):229~233.
[2] 张婷,田硕涵,周颖,等.重症坏死性胰腺炎患者使用头孢他啶/阿维巴坦的案例分析[J].中国临床药理学杂志,2020,36(11):1577~1579.
[3] 张宇艳,张海蓉,张景丽,等.连续性血液净化治疗重症急性胰腺炎的研究进展[J].临床肝胆病杂志,2020,36(6):1428~1432.
[4] 王兴鹏,李兆申,袁耀宗,等.中国急性胰腺炎诊治指南(2013,上海)[J].中华胰腺病杂志,2013,13(7):73~78.
[5] 郑筱萸.中药新药临床研究指导原则(试行)[M].中国医药科技出版社,2002.
[6] 翁文辉.中药大黄在重症急性胰腺炎治疗中的疗效观察[J].中国现代药物应用,2020,14(11):194~195.
[7] 王龙辉,刘群亮,周云鹏,等.肠型脂肪酸结合蛋白应用于重症急性胰腺炎胃肠道功能及病情评估的研究[J].中华普通外科学文献(电子版),2020,14(3):211~213.
[8] 龚曼芹,王宇静,王庆秋,等.脉冲高容量血液滤过对重症急性胰腺炎患者血清HMGB1的影响[J].中国现代医学杂志,2018,28(13):51~57.
[9] 闫克杰.97例重症胰腺炎患者伴腹腔感染穿刺标本的细菌培养与药敏试验结果分析[J].抗感染药学,2020,17(5):700~702.
[10] 姚佳柔,田彦璋,刘世洲.创伤递增式手术模式治疗重症急性胰腺炎[J].中华肝脏外科手术学电子杂志,2020,9(3):213~215.
[11] 符泉井,蔡奕龙,周杨.乌司他汀联合血液透析对重症胰腺炎患者血流动力学的影响[J].吉林医学,2020,41(6):1349~1350. |
|
|
|
2020, Vol. 26 
